Estudios Clínicos – Santa Cruz

Clinical Research

Clinical research is key to addressing complex diseases from a multidisciplinary perspective. In the field of medicine, it allows for the development and evaluation of innovative pharmacological treatments and therapies for conditions such as Alzheimer’s disease—improving patients’ quality of life and helping delay disease progression.

Leave us your information and we will contact you soon.

First Name

Last Name

Telephone

Select a Study

Comments

By checking the box, you agree to Santa Cruz Behavioral & Research Center terms and conditions. I understand that by submitting this information I may receive updates about Santa Cruz Behavioral, treatment protocols, research opportunities, programs and other information that may be of interest to me.

Alopecia Areata

TOGETHER-PsO is a clinical research study from Eli Lilly and Company. It is testing whether two investigational medicines (medicines being studied) may help treat people with plaque psoriasis who are overweight or living with obesity.

Vitiligo

Are you looking for ways to improve your vitiligo? Researchers are exploring possible ways to help. By participating in a clinical research study, you can join a community working to improve the future of vitiligo.

CALMA

The CALMA Clinical Trial is a Phase 2, FDA-registered research study for people living with Alzheimer’s disease who experience agitation. Agitation may include restlessness, pacing, repeated questions, irritability, verbal outbursts, or aggression. These symptoms can be very challenging for both patients and caregivers. The purpose of CALMA is to study an investigational medicine, IGC-AD1, an oral liquid solution containing tetrahydrocannabinol (THC) and melatonin. In earlier research, this medicine was shown to be safe and well tolerated. The current study is evaluating whether it can help reduce agitation symptoms while continuing to assess safety and tolerability.

Mind Set – 2

The MINDSET-2 Study is testing an oral study medication to determine whether it can safely help adults with Alzheimer’s disease preserve memory, thinking skills, and overall functioning.

ADEPT_ 4

The purpose of this study is to evaluate whether the investigational medication KarXT may help treat psychosis (delusions and/or hallucinations) in people with Alzheimer’s disease. Researchers hope to learn more about potential treatments that may reduce psychosis symptoms in individuals with Alzheimer’s-related psychosis.

Trailrunner-ALZ

If you have early-stage Alzheimer’s disease or are at risk of developing Alzheimer’s symptoms, the TRAILRUNNER-ALZ 3 study may be for you.

Atopic Dermatitis

Let’s break the cycle of atopic dermatitis.

Managing atopic dermatitis can often feel like trial and error. When treatments don’t work, the search for relief can be discouraging. You can play a key role in researchers’ efforts to change that story. Learn more about this study.

RENEW-Bipolar-1

Are you looking for a new way to manage bipolar disorder? If so, this study may be for you.

The study RENEW-Bipolar-1 is a clinical research study for adults with Bipolar I or II Disorder who are currently receiving treatment to manage their symptoms.

RENEW-MDD-1

Looking for a new way to

manage your depression?

RENEW-MDD-1 is a clinical research study for

adults with Major Depressive Disorder (MDD)

who are taking a treatment that is helping

manage their symptoms.

Axsome

If you or a loved one experiences symptoms associated with Alzheimer’s disease, is 65 years of age or older, and has a committed caregiver, you may be eligible to participate in a clinical research study evaluating an investigational medication. This study, conducted at select sites in the U.S. and Canada, offers the opportunity to contribute to the advancement of treatments for agitation associated with Alzheimer’s disease.

Alzheimer
Refocus ALZ

A clinical research study for individuals who may have early-stage Alzheimer’s disease or who may be at risk of developing Alzheimer’s symptoms.

IGC

If your loved one experiences agitation due to an Alzheimer’s diagnosis, they may be eligible for our clinical research study—no medical insurance required. Requirements: be between 60 and 99 years old, have a diagnosis of Alzheimer’s disease, experience daily agitation that affects their routine, and have a caregiver present at least 2 hours per day, 4 days per week.